1. AB0912 Two-year efficacy and safety of guselkumab for treatment of moderate-to-severe psoriasis: phase 3 voyage 1 trial. (12th June 2018) Authors: Griffiths, C.E.; Papp, K.A.; Kimball, A.B.; Randazzo, B.; Wasfi, Y.; Li, S.; Shen, Y.-K.; Blauvelt, A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Measuring the societal impact of psoriasis in the United Kingdom through a non‐interventional study of patients. (16th July 2017) Authors: Griffiths, C.E.; Williams, R.; Halliday, A.C.; Leman, J.A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 1(2018) Page Start: e5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0052 Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. (10th June 2014) Authors: Jani, M.; Chinoy, H.; Warren, R.B.; Fu, B.; Griffiths, C.E.; Morgan, A.W.; Wilson, G.; Hyrich, K.L.; Isaacs, J.D.; Barton, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 608 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗